Current progress on microRNAs‐based therapeutics in neurodegenerative diseases
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
MicroRNAs(miRNAs)‐based therapy has recently emerged as a promising strategy in the treatments of neurodegenerative diseases. Thus, in this review, the most recent and important challenges and advances on the development of miRNA therapeutics for brain targeting are discussed. In particular, this review highlights current knowledge and progress in the field of manufacturing, recovery, isolation, purification, and analysis of these therapeutic oligonucleotides. Finally, the available miRNA delivery systems are reviewed and an analysis is presented in what concerns to the current challenges that have to be addressed to ensure their specificity and efficacy. Overall, it is intended to provide a perspective on the future of miRNA‐based therapeutics, focusing the biotechnological approach to obtain miRNAs.WIREs RNA 2017, 8:e1409. doi: 10.1002/wrna.1409 This article is categorized under:RNA Processing > Processing of Small RNAs Regulatory RNAs/RNAi/Riboswitches > Regulatory RNAs RNA in Disease and Development > RNA in Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Nonviral vectors for gene delivery
Mintzer, M. A., & Simanek, E. E. (2009) · Chemical Reviews · doi:10.1021/cr800409e · Cited by 2,366 · cited 2×
“Nonetheless, the research focus over the last few decades has changed to the nonviral transport systems because of the advantages over viral vectors, namely the ability to safely deliver miRNA-based therapeutics in the specific site, with no or little immune response, relatively high drug loading, low production costs…”
BackgroundA brain-specific microRNA regulates dendritic spine development
Schratt, G. M., Tuebing, F., Nigh, E. A., Kane, C. G., Sabatini, M. E., Kiebler, M., & Greenberg, M. E. (2006) · Nature · doi:10.1038/nature04367 · Cited by 1,786
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609 · cited 1×
“Nanocarriers should be large enough to avoid fast clearance through the kidney excretion system and phagocytic uptake by RES, but small enough to penetrate the target cells.(102,128,129) Thus, nanocarriers can pass through endothelial cells of the BBB via endocytosis and adsorptive-mediated transcytosis (mechanisms wi…”
BackgroundMakeyev, E. V., Zhang, J., Carrasco, M. A., & Maniatis, T. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.07.015 · Cited by 1,395
Stark, A., Brennecke, J., Bushati, N., Russell, R. B., & Cohen, S. M. (2005) · Cell · doi:10.1016/j.cell.2005.11.023 · Cited by 1,080
A novel pathway regulates memory and plasticity via SIRT1 and miR-134
Gao, J., Wang, W.-Y., Mao, Y.-W., Gräff, J., Guan, J.-S., Pan, L., Mak, G., Kim, D., Su, S. C., & Tsai, L.-H. (2010) · Nature · doi:10.1038/nature09271 · Cited by 975
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943
Nonviral Gene Delivery: Principle, Limitations, and Recent Progress
Al-Dosari, M. S., & Gao, X. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9143-y · Cited by 706 · cited 1×
“Nanocarriers should be large enough to avoid fast clearance through the kidney excretion system and phagocytic uptake by RES, but small enough to penetrate the target cells.(102,128,129) Thus, nanocarriers can pass through endothelial cells of the BBB via endocytosis and adsorptive-mediated transcytosis (mechanisms wi…”
BackgroundDevelopment of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625 · cited 1×
“In turn, this advantage makes difficult to obtain highly pure and intact RNA because some chemical modifications can alter RNA structural dynamics (folding properties), biological activity, and safety profiles and, sometimes, are also associated with certain adverse effects, namely decrease on mRNA hybridization, acti…”
Background
Cited by
Gene therapy advances: A meta-analysis of AAV usage in clinical settings
Au, H. K. E., Isalan, M., & Mielcarek, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.809118 · Cited by 284
MicroRNA-based therapeutics in central nervous system injuries
Sun, P., Liu, D. Z., Jickling, G. C., Sharp, F. R., & Yin, K.-J. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18773871 · Cited by 228
Oligonucleotide therapies for disorders of the nervous system
Khorkova, O., & Wahlestedt, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3784 · Cited by 179
MicroRNAs change the games in central nervous system pharmacology
Marangon, D., Raffaele, S., Fumagalli, M., & Lecca, D. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.06.019 · Cited by 22
Metadata
- Authors
- Pereira, P., Queiroz, J. A., Figueiras, A., & Sousa, F.
- Venue
- WIREs RNA
- Publisher
- Wiley
- Published
- 2016-11-24
- Volume
- 8
- Issue
- 3
- ISSN
- 1757-7004 (ISSN-L)
- 1757-7012
- OpenAlex
- W2557806072
- Cited by
- 33
- References
- 18
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current progress on microRNAs‐based therapeutics in neurodegenerative diseases. https://app.cochat.ai/papers/10.1002/wrna.1409
- The paper
- Pereira, P., Queiroz, J. A., Figueiras, A., & Sousa, F. (2017). Current progress on microRNAs‐based therapeutics in neurodegenerative diseases. WIREs RNA. https://doi.org/10.1002/wrna.1409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.